Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

IPCAVD grant awarded in late 2007.

Safe Harbor Statement

All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

                             FINANCIAL TABLES FOLLOW


                              GEOVAX LABS, INC.
                        Statements of Operations Data
                  (amounts in thousands, except per share data)

                                 Three Months Ended      Year Ended
                                    December 31,         December 31,
                                  2008       2007      2008      2007
    Grant Revenue                 $612       $237     $2,910     $237

    Operating expenses:

'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
2. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
3. GeoVax to Present at the BIO CEO & Investor Conference 2009
4. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
5. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
8. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
9. GeoVax Further Strengthens Management Team
10. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 ... announced the addition of the  "Global Hormone ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,Hormone ... is a means of replacing hormones that ... body. This type of therapy is usually ...
(Date:8/21/2014)... Rochelle, N.Y. (PRWEB) August 21, 2014 ... is the first private college in the Mid-Hudson Region ... College will now begin accepting applications from qualified “high-technology” ... , “We are very pleased to have been selected ... support Governor Cuomo’s transformative initiative to stimulate economic development ...
(Date:8/21/2014)... OTC Markets Group Inc. ... company, on its approval to list on The ... the best marketplace for established U.S. and global ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We ... its growth strategy and achievement of this important ...
(Date:8/21/2014)... Pursuit Solutions ( http://www.pursuit-solutions.com ), a ... for Life Sciences sales and marketing organizations, announced ... Commercial Sales Models” by Peter Robinson, co-founder and ... examines some innovative models used to improve sales ... the pharmaceutical market. Robinson grades the industry on ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... Cephalon, Inc. (Nasdaq:,CEPH) announced today that the presentation ... JPMorgan Healthcare Conference are now available on the,"Investor Information" ... Tuesday, January 8, 2008, Frank Baldino, Jr.,Ph.D., Chairman and ... beginning at 2:00 p.m. Pacific Time (5 p.m. Eastern ...
... Staff to Continue Record of Investment Success -, ... operationally,independent worldwide biologics unit of AstraZeneca plc (LSE: ... venture capital fund,MedImmune Ventures, will broaden its focus ... by adding the therapeutic areas of,cardiovascular and metabolic ...
... With the SEC Shares Expected to ... HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/,--, ... Adjustments of,Evotec,s Consolidated Financial Statements With a Positive Net ... September 30 2007, Evotec AG (Frankfurt Stock Exchange: ...
Cached Biology Technology:Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 3Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 2Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 3Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 4Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 5
(Date:8/20/2014)... 20, 2014 George E. Fox, a John and Rebecca ... Houston (UH), was named a fellow in the International Society ... , Fox is one of four members two from ... chosen as fellows in 2014. Fellows are elected every three ... than 500 members from more than 20 countries, the ISSOL ...
(Date:8/20/2014)... Institute (HCI) at the University of Utah have identified ... BCR-ABL, the unregulated enzyme driving the blood cancer chronic ... nearly 6,000 new cases of CML will be diagnosed ... kinase inhibitors (TKIs), target BCR-ABL and are effective at ... control it in a way that allows patients to ...
(Date:8/20/2014)... /CNW/ -  Issue Serious allergic reactions ... life threatening for some children.    What you ... have food allergies and this number may be increasing, especially ... estimated to have food allergies.  The symptoms ... hives to breathing difficulties and loss of consciousness. Symptoms can ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... an avian influenza vaccine with doses as low as ... mixture known as MF59. The research is published in ... available online. , MF 59 is an adjuvant--a ... to a stimulus. For this research, the investigators used ...
... made international headlines in May 2006 when Colin Watson, ... after falling from a 12-meter tree, allegedly while hunting ... of Birds estimates that up to 30 of Britain's ... theory predicts that such exploitation is unlikely to extinguish ...
... C virus turns on human immune defenses upon entering ... manipulating interaction of key cellular proteins, UT Southwestern Medical ... "on/off switch" controls immunity against many viruses, highlighting a ... the researchers report. , In a study available ...
Cached Biology News:A human taste for rarity spells disaster for endangered species 2A human taste for rarity spells disaster for endangered species 3Molecular 'on/off switch' controls immune defenses against viruses 2
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: